A polymorphism of the μ-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans

被引:244
作者
Ray, LA [1 ]
Hutchison, KE [1 ]
机构
[1] Univ Colorado, Dept Psychol, Boulder, CO 80309 USA
关键词
alcohol; sensitivity; gene; phenotype; OPRM1;
D O I
10.1097/01.ALC.0000148114.34000.B9
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Recent research has implicated the endogenous opioid system in the development of alcohol use disorders. The A118G polymorphism of the OPRM1 gene has been shown to confer functional differences to mu-opioid receptors, such that the G variant binds beta-endorphin three times more strongly than the A variant. The goal of this study was to test whether the A118G polymorphism is associated with sensitivity to the effects of alcohol. Methods: Participants who were either homozygous for the A allele (eta = 23) or heterozygous (eta = 15) received intravenous doses of alcohol designed to reach three target levels of breath alcohol concentration: 0.02, 0.04, and 0.06. The testing procedure consisted of measures of subjective intoxication, stimulation, sedation, and mood states at baseline and at each of the three target breath alcohol concentrations. Results: The results suggested that individuals with the G allele reported higher subjective feelings of intoxication, stimulation, sedation, and happiness across trials as compared with participants with the A allele. Furthermore, participants with the G allele were almost three times more likely to report a positive family history of alcohol use disorders than participants with the A allele. Conclusions: These findings may help to explain previous research suggesting that naltrexone is more effective among individuals with the G allele. A medication that reduces feelings of euphoria after alcohol consumption may be more successful among individuals with a genetic predisposition to greater feelings of euphoria after consuming alcohol.
引用
收藏
页码:1789 / 1795
页数:7
相关论文
共 54 条
[1]   A review of research on the Alcohol Use Disorders Identification Test (AUDIT) [J].
Allen, JP ;
Litten, RZ ;
Fertig, JB ;
Babor, T .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1997, 21 (04) :613-619
[2]  
Anton RF, 1999, AM J PSYCHIAT, V156, P1758
[3]   A 6-month controlled naltrexon'e study:: Combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence [J].
Balldin, J ;
Berglund, M ;
Borg, S ;
Månsson, M ;
Bendtsen, P ;
Franck, J ;
Gustafsson, L ;
Halldin, J ;
Nilsson, LH ;
Stolt, G ;
Willander, A .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2003, 27 (07) :1142-1149
[4]   mu opioid receptor gene variants: lack of association with alcohol dependence [J].
Bergen, AW ;
Peterson, R ;
Kokoszka, J ;
Long, JC ;
Virkkunen, M ;
Linnoila, M ;
Goldman, D .
MOLECULAR PSYCHIATRY, 1997, 2 (06) :490-494
[5]   Endogenous opiates and behavior: 2002 [J].
Bodnar, RJ ;
Hadjimarkou, MM .
PEPTIDES, 2003, 24 (08) :1241-1302
[6]   Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity:: Possible implications for opiate addiction [J].
Bond, C ;
LaForge, KS ;
Tian, MT ;
Melia, D ;
Zhang, SW ;
Borg, L ;
Gong, JH ;
Schluger, J ;
Strong, JA ;
Leal, SM ;
Tischfield, JA ;
Kreek, MJ ;
Yu, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (16) :9608-9613
[7]   A genetic association study of the mu opioid receptor and severe opioid dependence [J].
Crowley, JJ ;
Oslin, DW ;
Patkar, AA ;
Gottheil, E ;
DeMaria, PA ;
O'Brien, CP ;
Berrettini, WH ;
Grice, DE .
PSYCHIATRIC GENETICS, 2003, 13 (03) :169-173
[8]  
DEWAELE JP, 1995, J PHARMACOL EXP THER, V275, P518
[9]   DISTRACTION DOES NOT IMPAIR MEMORY DURING INTOXICATION - SUPPORT FOR THE ATTENTION-ALLOCATION MODEL [J].
ERBLICH, J ;
EARLEYWINE, M .
JOURNAL OF STUDIES ON ALCOHOL, 1995, 56 (04) :444-448
[10]  
Franke P, 2001, AM J MED GENET, V105, P114, DOI 10.1002/1096-8628(20010108)105:1<114::AID-AJMG1074>3.0.CO